If Silvagen & Colloidal Silver is so Wonderful, Why Aren the Major Drug Companies Already Marketing It?
The medical establishment is driven largely by considerations of profitability. Drug companies spend many millions of dollars each year on research in the hope that they will discover a drug that may produce billions of dollars in profit. Their ideal is finding a drug that has a large market (Rogaine, Viagra) that cannot be readily duplicated in “me-too” drugs by other companies. The potential for massive profit justifies the expense of research and development. Colloidal silver fits part of this picture. It could serve a very large market. But this product fails to fit the rest of the picture. From the perspective of a drug company, this is not a drug. It is not a question of finding the right macromolecule with a highly specific set of properties. Rather, it is a question of developing a manufacturing process that produces a high quality colloidal solution of a common element. This is not their primary area of expertise. Actually, the economic situation is even worse for a drug compa
The medical establishment is driven largely by considerations of profitability. Drug companies spend many millions of dollars each year on research in the hope that they will discover a drug that may produce billions of dollars in profit. Their ideal is finding a drug that has a large market (Rogaine, Viagra) that cannot be readily duplicated in “me-too” drugs by other companies. The potential for massive profit justifies the expense of research and development. Colloidal silver fits part of this picture. It could serve a very large market. But this product fails to fit the rest of the picture. From the perspective of a drug company, this is not a drug. It is not a question of finding the right macromolecule with a highly specific set of properties. Rather, it is a question of developing a manufacturing process that produces a high quality colloidal solution of a common element. This is not their primary area of expertise.
The medical establishment is driven largely by considerations of profitability. Drug companies spend many millions of dollars each year on research in the hope that they will discover a drug that may produce billions of dollars in profit. Their ideal is finding a drug that has a large market (Rogaine, Viagra) that cannot be readily duplicated in “me-too” drugs by other companies. The potential for massive profit justifies the expense of research and development.Colloidal silver fits part of this picture. It could serve a very large market. But this product fails to fit the rest of the picture. From the perspective of a drug company, this is not a drug. It is not a question of finding the right macromolecule with a highly specific set of properties. Rather, it is a question of developing a manufacturing process that produces a high quality colloidal solution of a common element. This is not their primary area of expertise.Actually, the economic situation is even worse for a drug company
